Heart:研究发现,两年他汀一级预防,半数血脂不达标,其心血管风险增加22%

2019-04-21 朱柳媛 中国循环杂志

来自英国的一项全国性前瞻性队列研究显示,大约一半的心血管病一级预防人群在服用他汀类药物2年后,其胆固醇水平仍未达到“健康”状态,且未达标者风险增加。

来自英国的一项全国性前瞻性队列研究显示,大约一半的血管病一级预防人群在服用他汀类药物2年后,其胆固醇水平仍未达到“健康”状态,且未达标者风险增加。

所谓的“健康”状态,是指英国国立健康与临床优化研究所(NICE)指南提出的“应用他汀24个月内低密度脂蛋白胆固醇(LDL-C)水平降低40%”目标。研究者指出,要想达到这一目标,有必要针对高胆固醇血症患者给予个体化医疗。

该研究分析了英国临床实践研究数据链中的16.5万余人。这些人在启用他汀前无血管病,应用他汀进行心血管病一级预防

中位随访6.2年期间,发生了22 798例(13.8%)心血管事件,其中53.3%为LDL-C水平未达标者。

研究者发现,应用他汀24个月内,51.2%的患者LDL-C水平未达到NICE指南目标。校正年龄和基线未治疗时LDL-C水平等因素后,这些患者发生心血管事件的风险比LDL-C水平达标者增加22%。

在这些LDL-C水平未达标的患者中,LDL-C水平每下降1 mmol/L,脑卒中和轻型卒中发生风险仅降低6%;相应地,在LDL-C达标的患者中心血管病风险可降低13%。

研究者指出,这项观察性研究并不能得出因果关系,但反映的是真实世界经验,且纳入了大量患者,随访时间较长,因此应该也适用于别的患者群。

原始出处:
Akyea RK1, Kai J1, Qureshi N1,et al.Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease.Heart. 2019 Apr 15. pii: heartjnl-2018-314253. doi: 10.1136/heartjnl-2018-314253. [Epub ahead of print]

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2082500, encodeId=e79220825006a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Apr 02 00:08:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753466, encodeId=61f31e5346690, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Jun 19 09:08:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357169, encodeId=f6a1135e1699f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563088, encodeId=89b8156308801, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2082500, encodeId=e79220825006a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Apr 02 00:08:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753466, encodeId=61f31e5346690, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Jun 19 09:08:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357169, encodeId=f6a1135e1699f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563088, encodeId=89b8156308801, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2082500, encodeId=e79220825006a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Apr 02 00:08:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753466, encodeId=61f31e5346690, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Jun 19 09:08:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357169, encodeId=f6a1135e1699f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563088, encodeId=89b8156308801, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-23 zhaojie88
  4. [GetPortalCommentsPageByObjectIdResponse(id=2082500, encodeId=e79220825006a, content=<a href='/topic/show?id=56658981223' target=_blank style='color:#2F92EE;'>#血管风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89812, encryptionId=56658981223, topicName=血管风险)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/78FA0899509C358B01B975E8EAC1F88A/100, createdBy=7d822500145, createdName=ms5353107019656438, createdTime=Thu Apr 02 00:08:00 CST 2020, time=2020-04-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1753466, encodeId=61f31e5346690, content=<a href='/topic/show?id=6a57e33772b' target=_blank style='color:#2F92EE;'>#研究发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73377, encryptionId=6a57e33772b, topicName=研究发现)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e1736602208, createdName=hanhaisha2020, createdTime=Wed Jun 19 09:08:00 CST 2019, time=2019-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1357169, encodeId=f6a1135e1699f, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1563088, encodeId=89b8156308801, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Tue Apr 23 06:08:00 CST 2019, time=2019-04-23, status=1, ipAttribution=)]
    2019-04-23 slcumt

相关资讯

Lancet:Meta分析:≥75岁老年人吃他汀也可获益

据Lancet上发表的一项Meta分析,无论年龄大小,他汀类药物都能减少主要血管事件,包括75岁以上的老年人。

JAHA:他汀类药物依从性降低的心梗患者死亡风险**

许多急性心梗(AMI)后的老年患者在他汀类药物的依从性方面有所变化,但其与死亡率的相关性尚不清楚。本研究纳入了101011名2008-2010年年龄≥66岁的AMI住院患者,并对患者AMI前180天和AMI后180天的他汀类药物依从性进行了评估,分为非常不依从、轻中度不依从和依从三类。经过平均18个月时间的随访,20%的患者依从性明显提高,16%有所降低,14%患者无论AMI前还是AMI后均为不依

Brit J Clin Pharmacol:他汀增加糖尿病风险获新证,胖人和HbA1c高者应警惕

既往不少研究发现,他汀会升高糖尿病风险。近期发表的一项来自荷兰的前瞻性人群研究再次证实了这一点,且超重、肥胖和糖尿病前期人群应用他汀时风险尤其高。

糖尿病与他汀的纠葛,这8大要点你必须掌握!

糖尿病患者服用他汀要注意些什么?甲减患者要注意哪些?他汀会增高血糖吗?肝功能轻中度异常能用他汀治疗吗?打消疑惑,这8大要点助你掌握!

JAHA:他汀类药物与糖尿病发生呈时间剂量相关性

他汀类药物被越来越广泛地用于一级预防,但是他汀药物与糖尿病发生的相关性问题不容忽视。本研究纳入了2005-2012年年龄≥40岁的复合他汀类药物适应症的高血脂患者,主要终点事件是接受药物治疗后的新发糖尿病。在2162119名复合他汀药物治疗适应症的高血脂患者中,有29.5%患者曾经使用过他汀类药物,经过平均3.9年时间的随访,相比于从没使用过他汀药物患者,使用过他汀药物患者的糖尿病风险明显更高(H

"肝功能异常"能否使用他汀?

对于转氨酶轻中度异常的患者,临床医生往往拒绝为其应用他汀治疗。这种做法是不尽合理的。对于肝功能异常的患者,应鉴别其具体病因。若是由活动性肝炎等严重肝病所致的转氨酶升高,不应启动他汀治疗。